Analytical Data
-
Gene name
DR5
- Application
-
Alternative Names
CD262; TNFRSF10B; KILLER; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; ZTNFR9; Death receptor 5; TNF-related apoptosis-inducing ligand receptor 2; Tumor Necrosis Factor Receptor Superfamily, Member 10B
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14763
-
Expression Region
Ser234~Ala435
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DR5, or Death Receptor 5, is a crucial member of the tumor necrosis factor receptor (TNFR) superfamily, playing a pivotal role in mediating apoptosis in various cell types. Research into DR5 has gained considerable attention due to its potential implications in cancer therapy, where the activation of this receptor can lead to programmed cell death in tumor cells, thereby inhibiting tumor growth. The use of recombinant DR5 proteins has emerged as a promising strategy for enhancing anti-cancer immune responses, particularly through the development of agonistic antibodies or CAR T-cell therapies targeting DR5. Studies have demonstrated that engaging DR5 can trigger apoptosis in malignancies resistant to conventional therapies, highlighting its importance as a target for drug development. Additionally, the elucidation of DR5's signaling pathways has provided insights into the complex mechanisms of cell death and survival, paving the way for novel therapeutic approaches. Ongoing research aims to optimize DR5-based therapies, enhance their specificity, improve their efficacy, and minimize potential side effects, making DR5 a focal point in the design of innovative cancer treatments that harness the body's immune system to combat tumors effectively. As a result, understanding the structural and functional characteristics of DR5 recombinant proteins is critical for advancing their therapeutic applications in oncology.
